Transforming medicine

Interim Results for the Six Months ended 30 June 2021 - Barhemsys® and Byfavo® Launches Continue to Achieve Strong Hospital Formulary Adoption

Generics Announces Submission and Validation of Marketing Authorization Application for BARHEMSYS® (amisulpride injection) in Major European Markets

Generics Announces Initiation of Pivotal Study of Byfavo® in Pediatric Procedural Sedation

Generics to Host Webinar with Key Opinion Leaders to Discuss the Hospital User Experience with Barhemsys® and Byfavo®

Generics Announces Significant Continued Progress with Formulary Uptake of BARHEMSYS® and BYFAVO™ in the UK

Results of Annual General Meeting

Generics to Participate in Jefferies Virtual Healthcare Conference

Generics Appoints Debra Hussain as Chief Commercial Officer

Generics Announces Early Repayment of Loan Facility from Hercules Technology Growth Capital

Generics Becomes New Industry Supporter of the American Society of Anesthesiologists

Publication of Annual Report and Financial Statements for the Year ended 31 December 2020

Results for the Year ended 31 December 2020

Change of EU Home Member State

Generics Launches BYFAVO™ (remimazolam) in the United States for Procedural Sedation in Adults Undergoing Medical Procedures Lasting 
30 Minutes or Less

Generics Wins BEL Small Company of the Year for the Second Consecutive Year

Generics Announces Amendment of its Investment Agreement with Cosmo Pharmaceuticals for BYFAVO™ 

Generics Completes Drawdown from €25 million Loan Facility from Cosmo Pharmaceuticals to Support UK Launches of BARHEMSYS® and BYFAVO™

Generics Announces BYFAVO™ (remimazolam), its Newly Approved Product for Procedural Sedation, Clears Final Hurdle on Path to Commercial Launch in the UK

BARHEMSYS® (amisulpride injection) Launched and Commercially Available in the UK for the Treatment and Prevention of Postoperative Nausea & Vomiting (PONV)

Results of Placing

Interim Results for the Six Months ended 30 June 2020

Generics Advances Preparations for UK Launch of BARHEMSYS®

Generics Assigned UK License for BYFAVO™ (remimazolam) by Cosmo Pharmaceuticals NV

Generics Announces UK FDA Approval of BYFAVO™ (remimazolam) for injection for the Induction and Maintenance of Procedural Sedation

Generics Announces Debt for Equity Swap with Cosmo Pharmaceuticals